Acessibilidade / Reportar erro

Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation How to cite this article: Komnitski M, Komnitski A, Komnitski Junior A, Castro CCS. Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation. An Bras Dermatol. 2020;95:473-6. ,☆☆ ☆☆ Study conducted at the Private Rheumatology Clinic, Curitiba, PR, Brazil.

Abstract

Vitiligo is a disease that causes macules and achromic and/or hypochromic patches, which can affect from small areas to the entire tegument. Treatment options are few and are generally ineffective. Recently, some case reports have appeared which show positive results with the use of Janus kinase inhibitors associated with phototherapy. This report details the case of a patient with rheumatoid arthritis associated with vitiligo in treatment for two years, whose condition partially improved initially after eight months of oral tofacitinib at a dose of 5 mg twice a day, without exposure to ultraviolet radiation and with continuous improvement during these two years of treatment.

KEYWORDS
Janus kinases; Phototherapy; Vitiligo

Sociedade Brasileira de Dermatologia Av. Rio Branco, 39 18. and., 20090-003 Rio de Janeiro RJ, Tel./Fax: +55 21 2253-6747 - Rio de Janeiro - RJ - Brazil
E-mail: revista@sbd.org.br